Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Summary by Globe Newswire
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers ...

8 Articles

The Toronto StarThe Toronto Star
+7 Reposted by 7 other sources
Lean Left

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers

·Toronto, Canada
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 72% of the sources lean Left
72% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Tuesday, July 14, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

Neuroscience icon

Neuroscience

St. Catharines icon

St. Catharines

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal